[Form 4] Nautilus Biotechnology, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Nautilus Biotechnology director Farzad Nazem received a grant of stock options covering 45,000 shares of common stock. The options have an exercise price of $2.28 per share and expire on June 18, 2036. All 45,000 options are held directly after this grant.

According to the grant’s terms, one-twelfth of the options vest each month following the grant date, as long as Nazem continues to serve as a “Service Provider” under Nautilus’s 2021 Equity Incentive Plan. This creates a 12‑month, time-based vesting schedule tied to ongoing service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider NAZEM FARZAD

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	45,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 45,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 45,000 options Exercise price: $2.28 per share Expiration date: June 18, 2036 +1 more

4 metrics

Options granted 45,000 options Stock Option (Right to Buy) grant to director Farzad Nazem

Exercise price $2.28 per share Conversion or exercise price of granted stock options

Expiration date June 18, 2036 Option expiration for the 45,000 granted options

Post-grant option holdings 45,000 options Total stock options held directly after this transaction

Key Terms

Stock Option (Right to Buy), 2021 Equity Incentive Plan, Service Provider, vesting

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

2021 Equity Incentive Plan financial

"the Issuer's 2021 Equity Incentive Plan through each applicable vesting date"

Service Provider financial

"continuous status as a "Service Provider" through each applicable vesting date"

vesting financial

"one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

NAZEM FARZAD

(Last) (First) (Middle)

C/O NAUTILUS BIOTECHNOLOGY, INC.

2701 EASTLAKE AVE. E.

(Street)

SEATTLE WASHINGTON 98102

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nautilus Biotechnology, Inc. [ NAUT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.28	06/18/2026		A		45,000		(1)	06/18/2036	Common Stock	45,000	$0	45,000	D

Explanation of Responses:

1. Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month).

Remarks:

	/s/ Matthew B. Murphy, as Attorney-in-Fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Nautilus Biotechnology (NAUT) disclose in this Form 4?

Nautilus Biotechnology disclosed that director Farzad Nazem received a grant of 45,000 stock options. These options give him the right to buy common shares at a fixed exercise price, subject to a time-based vesting schedule tied to his continued service.

How many Nautilus (NAUT) stock options were granted to director Farzad Nazem?

Farzad Nazem was granted 45,000 stock options for Nautilus common stock. All 45,000 options are held directly following this grant and represent a compensation award rather than an open-market purchase, with vesting over time based on continued service to the company.

What is the exercise price and expiration date of the NAUT options granted to Farzad Nazem?

The granted Nautilus options have an exercise price of $2.28 per share and expire on June 18, 2036. This means Nazem can choose to exercise the options at that fixed price any time before expiration, subject to the options having vested under the plan’s terms.

How do the Nautilus (NAUT) options granted to Farzad Nazem vest over time?

The options vest in equal monthly installments over 12 months, with one-twelfth of the total vesting each month after the grant date. Vesting is conditioned on Nazem’s continuous status as a “Service Provider” under Nautilus’s 2021 Equity Incentive Plan throughout the applicable vesting dates.

Was Farzad Nazem’s Nautilus (NAUT) Form 4 transaction an open-market stock purchase or a compensation award?

The Form 4 reports a compensation-related award, not an open-market purchase. Nazem received 45,000 stock options at a $2.28 exercise price as a grant under the company’s equity incentive plan, with vesting tied to his ongoing service rather than a cash transaction in the market.